AI Article Synopsis
Article Abstract
Background: RTXM83 is a rituximab biosimilar with proven clinical safety and efficacy. It is the first rituximab biosimilar developed and approved in South America and is currently marketed in several Latin American, Middle Eastern and African countries.
Objective: The aim of this study was to present the physicochemical and biological characterization studies utilized to demonstrate the similarity between RTXM83 and its reference product.
Methods: Primary and higher order protein structures were analysed using peptide mapping with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), fluorescence spectroscopy and circular dichroism, and micro-differential scanning calorimetry, among other techniques. Charge variants were determined by cation-exchange chromatography (CEX) and capillary isoelectric focusing (cIEF). Glycosylation and glycoforms distribution were analysed using MS, normal phase high-performance liquid chromatography (NP-HPLC) and high-performance anion-exchange chromatography with pulsed amperometric detection (HPAE-PAD). Size variants were evaluated by size-exclusion chromatography (SEC), sedimentation velocity analytical ultracentrifugation (SV-AUC), dynamic light scattering (DLS), and capillary electrophoresis-sodium dodecyl sulfate (CE-SDS). Biological characterization included binding assays for complement C1q, CD20, and several Fc receptors (FcRs), as well as potency determination for in vitro apoptosis induction, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated cytotoxicity (ADCC).
Results: RTXM83 and the reference product showed identical primary sequences and disulfide bridge patterns, and similarity at higher order protein structures, post-translational modification profiles (amino acid modifications, charge variants, and glycosylation) and levels of purity and process-related impurities. Functional studies demonstrated that RTXM83 is similar to the reference product regarding the three known mechanisms of action of rituximab: CDC, ADCC, and apoptosis induction. Binding affinities to CD20, complement component C1q, and different FcRs were also equivalent.
Conclusion: RTXM83 is similar to its reference product in all critical quality attributes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40259-019-00349-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma.
Oncol Ther
September 2024
Medical Affairs, Libbs Farmacêutica, São Paulo, São Paulo, Brazil.
Article Synopsis
- RTXM83, a biosimilar to rituximab, has been approved after extensive studies showed it is similar to the original drug; this includes results from a pivotal study called RTXM83-AC-01-11.
- A retrospective study in Brazil analyzed long-term outcomes for patients with diffuse large B cell lymphoma (DLBCL) who received either RTXM83 or the original rituximab alongside other chemotherapy drugs, revealing that both groups showed significant progress in treatment.
- The findings highlighted that RTXM83 had a much higher progression-free survival and overall survival rate compared to the original drug, indicating its effectiveness and safety, although further research is needed to confirm these results in
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Leuk Lymphoma
December 2019
mAbxience Research S.L., Madrid, Spain.
This multicenter, double-blind, randomized study compared the efficacy, pharmacokinetics (PKs)/pharmacodynamics (PDs), safety and immunogenicity profile of RTXM83 vs. reference rituximab (R-rituximab), both with CHOP, as first-line treatment of diffuse large B-cell lymphoma (DLBCL). A total of 272 patients <65 years of age, with good prognosis (136 per arm) were randomized (1:1) to receive six cycles of either RTXM83 or R-rituximab.
View Article and Find Full Text PDFPhysicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
BioDrugs
June 2019
mAbxience, Carlos Villate 5148, Munro, B1605AXL, Buenos Aires, Argentina.
Background: RTXM83 is a rituximab biosimilar with proven clinical safety and efficacy. It is the first rituximab biosimilar developed and approved in South America and is currently marketed in several Latin American, Middle Eastern and African countries.
Objective: The aim of this study was to present the physicochemical and biological characterization studies utilized to demonstrate the similarity between RTXM83 and its reference product.
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Cancer Chemother Pharmacol
March 2018
mAbxience Research S.L., Manuel Pombo Angulo 28, 28050, Madrid, Spain.
Purpose: The main objective was to quantify any potential differences in pharmacokinetic (PK) parameters (AUC and C) between RTXM83, a proposed rituximab biosimilar, and its reference product, using a population PK model approach.
Methods: Rituximab PK and PD data were obtained from a randomized, double-blind, phase III clinical study (RTXM83-AC-01-11) in patients with diffuse large B-cell lymphoma (DLBCL) that received 375 mg/m intravenous RTXM83 or its reference product with CHOP regimen, every 3 weeks, for six cycles. Rituximab levels were quantified by Meso Scale Discovery assay.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!